Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

New England Journal of Medicine

Volumn 377, Issue 14, 2017, Pages 1345-1356

  Wolchok, J D ^a   Chiarion Sileni, V ^b   Gonzalez, R ^g   Rutkowski, P ^h   Grob, J J ⁱ   Cowey, C L ^k   Lao, C D ^l   Wagstaff, J ^m   Schadendorf, D ^p   Ferrucci, P F ^c   Smylie, M ^q   Dummer, R ^s   Hill, A ^t   Hogg, D ^r   Haanen, J ^y   Carlino, M S ^u   Bechter, O ^z   Maio, M ^d   Marquez Rodas, I ^aa   Guidoboni, M ^e   McArthur, G ^w   Lebbe C ^j   Ascierto, P A ^f   Long, G V ^v   Cebon, J ^x   Sosman, J ^ab   Postow, M A ^a   Callahan, M K ^a   Walker, D ^ac   Rollin, L ^ac   Bhore, R ^ac   Hodi, F S ^ad   Larkin, J ^n,o   more..

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d UNIVERSITY HOSPITAL OF SIENA   (Italy)

^e DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g UNIVERSITY OF COLORADO   (United States)

^h INSTITUTE OF ONCOLOGY   (Poland)

ⁱ AIX MARSEILLE UNIVERSITY   (France)

^j INSERM   (France)

^k TEXAS ONCOLOGY   (United States)

^l UNIVERSITY OF MICHIGAN   (United States)

^m SWANSEA UNIVERSITY   (United Kingdom)

ⁿ INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^o UNIVERSITY OF DUISBURG ESSEN   (Germany)

^p GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^q CROSS CANCER INSTITUTE   (Canada)

^r PRINCESS MARGARET HOSPITAL   (Canada)

^s UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^t Tasman Oncology Research   (Australia)

^u UNIVERSITY OF SYDNEY   (Australia)

^v Royal North Shore and Mater Hospitals   (Australia)

^w PETER MACCALLUM CANCER CENTRE   (Australia)

^x UNIVERSITY OF MELBOURNE   (Australia)

^y NETHERLANDS CANCER INSTITUTE   (Netherlands)

^z UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^aa HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^ab NORTHWESTERN UNIVERSITY   (United States)

^ac BRISTOL MYERS SQUIBB   (United States)

^ad DANA FARBER CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; IPILIMUMAB; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; TRIACYLGLYCEROL LIPASE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; COLITIS; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEVER; FOLLOW UP; GOOD CLINICAL PRACTICE; HEADACHE; HUMAN; HUMAN TISSUE; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOTHYROIDISM; INSTITUTIONAL REVIEW; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MELANOMA; NAUSEA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SURVIVAL TIME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VITILIGO; VOMITING; WEIGHT REDUCTION; AGED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; SKIN NEOPLASMS; SURVIVAL RATE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; HUMANS; KAPLAN-MEIER ESTIMATE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 85030460514     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1709684     Document Type: Article

References (15)

1. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
2. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
3. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015;33:1889-94.
4. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.
5. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372:2521-32.
6. Robert C, Long GV, Schachter J, et al. Long-term outcomes in patients (pts) with ipilimumab (ipi)-naïve advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment. J Clin Oncol 2017;15:Suppl:35. abstract.
7. Sznol M, Callahan MK, Kluger H, et al. Updated survival, response and safety data in a phase 1 dose-finding study (CA209-004) of concurrent nivolumab (NIVO) and ipilimumab (IPI) in advanced melanoma. Presented at the Society for Melanoma Research Annual Meeting, San Francisco, November 18–21, 2015. abstract.
8. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372:2006-17.
9. Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 2016;17:1558-68.
10. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Overall survival results from a phase III trial of nivolumab combined with ipilimumab in treatment-naïve patients with advanced melanoma (CheckMate 067). Presented at the American Association for Cancer Research Annual Meeting, Washington, DC, April 1–5, 2017. abstract.
11. Hochberg Y. A sharper Bonferroni procedure for multiple significance testing. Biometrika 1988;75:800-2.
12. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000;56:337-44.
13. Linden A. Measuring diagnostic and predictive accuracy in disease management: an introduction to receiver operating characteristic (ROC) analysis. J Eval Clin Pract 2006;12:132-9.
14. Long GV, Flaherty KT, Stroyakovskiy D, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol 2017 May 5 (Epub ahead of print).
15. Ribas A, Martin-Algarra S, Bhatia S, et al. Immunomodulatory effects of nivolumab and ipilimumab in combination or nivolumab monotherapy in advanced melanoma patients: CheckMate 038. Presented at the American Association for Cancer Research Annual Meeting, Washington, DC, April 1–5, 2017. abstract.